Skip to main content
OpenTrials

Clinical trial condition

Histiocytic Disorders, Malignant

Explore clinical trials studying Histiocytic Disorders, Malignant. Study availability and eligibility vary by location and protocol.

260 public trials 43 recruiting studies
Refine in advanced search Browse all conditions

Histiocytic Disorders, Malignant trial results

Active, Not Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details
Active, Not Recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748

Conditions
AML/MDS, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, +33 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • TriStar Bone Marrow Transplant Nashville, Tennessee, United States
View Trial Details
Active, Not Recruiting

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT05563844

Conditions
Dendritic Cell Sarcoma, Interdigitating, Diffuse Large B Cell Lymphoma，DLBCL, Hemic and Lymphatic Diseases, +5 more
Locations
  • Ruijin Hospital of Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
  • West China Hospital of Sichuan University Chengdu, Sichuan, China
View Trial Details
Active, Not Recruiting

An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

NCT06734078

Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations
  • IRCCS Azienda Ospedaliero - Universitaria di Bologna Bologna, Italy
  • Casa Sollievo della Sofferenza - Reparto di Oncoematologia San Giovanni Rotondo, Foggia, Italy
  • Azienda Ospedaliera Universitaria- Policlinico di Bari Bari, Italy
  • Ospedale Oncologico Armando Businco Cagliari, Italy
View Trial Details
Active, Not Recruiting

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

NCT03386513

Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, Disease Attributes, +25 more
Locations
  • Banner Health MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Medical Center Duarte, California, United States
  • UCLA Los Angeles, California, United States
  • Stanford Stanford, California, United States
View all 28 locations
View Trial Details
Active, Not Recruiting

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT03064867

Conditions
Dendritic Cell Sarcoma, Interdigitating, Diffuse Large B-cell-lymphoma, Hemic and Lymphatic Diseases, +5 more
Locations
  • Washington University School of Medicine, Siteman Cancer Center St Louis, Missouri, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details

Related conditions